These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11256201)

  • 21. Effect of a single IV administration of L-propionylcarnitine on myocardial microcirculation assessed by coronary flow velocity reserve measurement in patients with systemic sclerosis: a pilot study.
    Montisci R; Ruscazio M; Lai S; Vacca A; Cauli A; Passiu G; Montisci M; Meloni L; Mathieu A; Iliceto S
    Clin Ther; 2007 Jan; 29(1):163-71. PubMed ID: 17379056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of abnormal blood flow and efficacy of treatment in patients with systemic sclerosis using a newly developed microwireless laser Doppler flowmeter and arm-raising test.
    Kido M; Takeuchi S; Hayashida S; Urabe K; Sawada R; Furue M
    Br J Dermatol; 2007 Oct; 157(4):690-7. PubMed ID: 17640308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Associations of right ventricular myocardial function with skin and pulmonary involvement in asymptomatic patients with systemic sclerosis.
    D'Andrea A; Bellissimo S; Scotto di Uccio F; Vigorito F; Moscato F; Tozzi N; Di Donato M; Citro R; Stisi S; Scherillo M
    Ital Heart J; 2004 Nov; 5(11):831-9. PubMed ID: 15633438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased prevalence of scleroderma in southwestern Ontario: a cluster analysis.
    Thompson AE; Pope JE
    J Rheumatol; 2002 Sep; 29(9):1867-73. PubMed ID: 12233880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased arterial stiffness as the marker of vascular involvement in systemic sclerosis.
    Timár O; Soltész P; Szamosi S; Dér H; Szántó S; Szekanecz Z; Szücs G
    J Rheumatol; 2008 Jul; 35(7):1329-33. PubMed ID: 18484693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parenchymal and vascular interactions in the pathogenesis of nonspecific interstitial pneumonia in systemic sclerosis and idiopathic interstitial pneumonia.
    Franco de Carvalho E; Parra ER; de Souza R; Muxfeldt A'b Saber A; Capelozzi VL
    Respiration; 2008; 76(2):146-53. PubMed ID: 18073456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Juvenile systemic sclerosis: a follow-up study of eight patients.
    Szamosi S; Maródi L; Czirják L; Ellenes Z; Szücs G
    Ann N Y Acad Sci; 2005 Jun; 1051():229-34. PubMed ID: 16126963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients.
    Nikou GC; Toumpanakis C; Katsiari C; Charalambopoulos D; Sfikakis PP
    J Clin Rheumatol; 2007 Jun; 13(3):119-23. PubMed ID: 17551375
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis.
    Cutolo M; Pizzorni C; Tuccio M; Burroni A; Craviotto C; Basso M; Seriolo B; Sulli A
    Rheumatology (Oxford); 2004 Jun; 43(6):719-26. PubMed ID: 15026581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased prevalence of ocular glaucomatous abnormalities in systemic sclerosis.
    Allanore Y; Parc C; Monnet D; Brézin AP; Kahan A
    Ann Rheum Dis; 2004 Oct; 63(10):1276-8. PubMed ID: 15361386
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Survival time of progressive systemic sclerosis patients treated with immunosuppressive drugs].
    Olszewska Z
    Przegl Dermatol; 1989; 76(5-6):430-4. PubMed ID: 2641810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcome of small-bowel motor impairment in systemic sclerosis--a prospective manometric 5-yr follow-up.
    Marie I; Ducrotté P; Denis P; Hellot MF; Levesque H
    Rheumatology (Oxford); 2007 Jan; 46(1):150-3. PubMed ID: 16782730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A; Abou-Raya S; Helmii M
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel treatment for limited mouth opening due to facial fibrosis: A case series.
    Hoverson K; Love T; Lam TK; Marquart JD
    J Am Acad Dermatol; 2018 Jan; 78(1):190-192. PubMed ID: 29241782
    [No Abstract]   [Full Text] [Related]  

  • 35. Recommendations for the care of oral involvement in patients with systemic sclerosis.
    Alantar A; Cabane J; Hachulla E; Princ G; Ginisty D; Hassin M; Sorel M; Maman L; Pilat A; Mouthon L
    Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1126-33. PubMed ID: 21485023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Autologous fat grafting in the treatment of fibrotic perioral changes in patients with systemic sclerosis.
    Del Papa N; Caviggioli F; Sambataro D; Zaccara E; Vinci V; Di Luca G; Parafioriti A; Armiraglio E; Maglione W; Polosa R; Klinger F; Klinger M
    Cell Transplant; 2015; 24(1):63-72. PubMed ID: 25606975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The spectrum of orofacial manifestations in systemic sclerosis: a challenging management.
    Jung S; Martin T; Schmittbuhl M; Huck O
    Oral Dis; 2017 May; 23(4):424-439. PubMed ID: 27196369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Responders to cyclophosphamide: results of a single-centre analysis among systemic sclerosis patients.
    Becker MO; Schohe A; Weinert K; Huscher D; Schneider U; Burmester GR; Riemekasten G
    Ann Rheum Dis; 2012 Dec; 71(12):2061-2. PubMed ID: 22689320
    [No Abstract]   [Full Text] [Related]  

  • 39. Risk factors for malignancy in systemic sclerosis patients.
    Kaşifoğlu T; Yaşar Bilge Ş; Yıldız F; Özen G; Pehlivan Y; Yılmaz N; Tarhan F; Yılmaz S; Küçük A; Emmungil H; Koca SS; Çınar M; Direskeneli H; Erken E; Can G; Özmen M; Gönüllü E; Kisacik B; Aksu K; Karadağ O; Kasifoglu N; Arslantas D; Sahin F; Keser G; Yavuz S; Birlik M; Onat AM
    Clin Rheumatol; 2016 Jun; 35(6):1529-33. PubMed ID: 27118199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variation of urinary acid glycosaminoglycan and collagen metabolite excretion with disease activity in generalized scleroderma.
    Blumenkrantz N; Asboe-Hansen G
    Acta Derm Venereol; 1980; 60(1):39-43. PubMed ID: 6153832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.